These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12570677)

  • 1. Cytokine therapeutics for the treatment of sepsis: why has nothing worked?
    Remick DG
    Curr Pharm Des; 2003; 9(1):75-82. PubMed ID: 12570677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The physiologic basis for anticytokine clinical trials in the treatment of sepsis.
    Cain BS; Meldrum DR; Harken AH; McIntyre RC
    J Am Coll Surg; 1998 Mar; 186(3):337-50. PubMed ID: 9510266
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of cytokines in sepsis.
    Hack CE; Aarden LA; Thijs LG
    Adv Immunol; 1997; 66():101-95. PubMed ID: 9328641
    [No Abstract]   [Full Text] [Related]  

  • 4. Endotoxin, sepsis, and the primrose path.
    O'Reilly M; Newcomb DE; Remick D
    Shock; 1999 Dec; 12(6):411-20. PubMed ID: 10588508
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytokine blockade in sepsis--Are two better than one?
    Hotchkiss RS; Karl IE
    Crit Care Med; 2001 Mar; 29(3):671-2. PubMed ID: 11373443
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytokines and anticytokines in the pathogenesis of sepsis.
    van der Poll T; van Deventer SJ
    Infect Dis Clin North Am; 1999 Jun; 13(2):413-26, ix. PubMed ID: 10340175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome.
    Dinarello CA; Gelfand JA; Wolff SM
    JAMA; 1993 Apr; 269(14):1829-35. PubMed ID: 8459516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targets for sepsis therapies: tumor necrosis factor versus interleukin-1.
    Russell DA; Thompson RC
    Curr Opin Biotechnol; 1993 Dec; 4(6):714-21. PubMed ID: 7764470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticytokine strategies for the treatment of septic shock: relevance of animal models.
    Heumann D; Glauser MP
    Curr Top Microbiol Immunol; 1996; 216():299-311. PubMed ID: 8791746
    [No Abstract]   [Full Text] [Related]  

  • 10. From cellular receptors to transduction-transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation?
    Dayer JM; Molnarfi N; Burger D
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S83-96. PubMed ID: 16187943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality.
    Remick DG; Call DR; Ebong SJ; Newcomb DE; Nybom P; Nemzek JA; Bolgos GE
    Crit Care Med; 2001 Mar; 29(3):473-81. PubMed ID: 11373406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine modulation in sepsis and septic shock.
    Zanotti S; Kumar A; Kumar A
    Expert Opin Investig Drugs; 2002 Aug; 11(8):1061-75. PubMed ID: 12150702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of cytokine responses in sepsis.
    Lowry SF; Moldawer LL
    Ann N Y Acad Sci; 1993 Jun; 685():471-82. PubMed ID: 8363256
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved clinical survival from sepsis.
    Freeman BD; Buchman TG
    J Am Coll Surg; 1998 Mar; 186(3):350-1. PubMed ID: 9510267
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of tumor necrosis factor in sepsis.
    Spooner CE; Markowitz NP; Saravolatz LD
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S11-7. PubMed ID: 1370262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological response modifiers in the management of rheumatoid arthritis.
    Louie SG; Park B; Yoon H
    Am J Health Syst Pharm; 2003 Feb; 60(4):346-55. PubMed ID: 12625216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine inhibition as a strategy for treating systemic lupus erythematosus.
    Clark DN; Markham JL; Sloan CS; Poole BD
    Clin Immunol; 2013 Sep; 148(3):335-43. PubMed ID: 23200699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
    Charles P; Elliott MJ; Davis D; Potter A; Kalden JR; Antoni C; Breedveld FC; Smolen JS; Eberl G; deWoody K; Feldmann M; Maini RN
    J Immunol; 1999 Aug; 163(3):1521-8. PubMed ID: 10415055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic approaches in sepsis: a critical review.
    Eidelman LA; Pizov R; Sprung CL
    Intensive Care Med; 1995 Nov; 21 Suppl 2():S269-72. PubMed ID: 8636535
    [No Abstract]   [Full Text] [Related]  

  • 20. Unopposed interleukin-1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis.
    Slotman GJ; Quinn JV; Wry PC; Brathwaite CE; Friedman BM
    Ann Surg; 1997 Jul; 226(1):77-84. PubMed ID: 9242341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.